VCI Partners - Investor Profile and Portfolio

Minimally invasive ultrasonic medical devices for chronic tendon pain treatment. The company pioneers minimally invasive solutions for chronic tendon pain, utilizing ultrasonic technology to precisely target and remove damaged tissue. This innovative approach aims to restore healthy musculoskeletal function with less downtime than traditional surgery. They focus on providing patients with a solution to alleviate suffering and improve their quality of life. Their technology offers a breakthrough for treating chronic tendinopathy, enabling quicker recovery and a return to activity. They are dedicated to advancing medical technology and improving patient outcomes in the field of musculoskeletal health.

Provider of direct-to-consumer, non-clinical genetic tests. It uses RT-PCR and DxTerity's proprietary DxDirect chemistry for the development of assay, DxDirect, a technique for analysis of gene signatures that combines chemical ligation process, NEAT, and sample stabilization system, DxCollect. Using DxTerity's genomics platform, fingerstick blood can be safely collected and shipped to DxTerity via US mail for non-clinical analysis.

Provider of RFID-based event and venue management solutions. These solutions encompass access control and management, accreditation and credential management, patron engagement tools, premium hospitality services, and RFID retail checkout systems. The technology offers layered access control, personalized guest experiences, and real-time tracking of patron and staff movement for improved operational efficiency and post-event analysis. Services are customizable to suit various event sizes and venue types, providing clients with enhanced security, control, and operational intelligence. The solutions leverage RFID technology to deliver speed, control, intelligence, visibility, security, and personalization.